Redeye is positively surprised by I-Tech’s very strong end of 2022, posting organic sales growth of ...
Sales SEK 721m -13% vs. ABGSCe 824m Adj. EBITDA SEK 13.
Higher sales, but also higher losses Solid demand outlook, some caution on margins Margins and neg.
Sales -7% vs ABGSCe, adj. EBITA -7% vs ABGSCe Outlook uncertain, '23e-'24e adj.
Scanfil’s year concluded on a strong note without any big surprises.
Redeye comments on Zordix Q4-report which saw revenue in line with expectations while EBITDA came in...
Atria reported Q4 adjusted EBIT of EUR 16.7m, 39% above our estimate (no quality consensus available...
Raketech just released a solid Q4 report, and a better than expected start to the first quarter.
Redeye saw sales lower than our expectations in the Q4 report partly due to the delays for Carbonhan...
Q4 results Arise delivered sales of SEK 106m, which was 10% below our expectations of SEK 118m.
Redeye notes that Egetis’ Q4 report presented SEK5.
Redeye is encouraged by the news that Zwipe starts the first proof-of-concept together with Civix fo...
Q4 outcome Q4 sales came in at SEK 1,606m (+88% y-o-y growth, driven largely by acquisitions) and ad...
Redeye comments on Savelend’s Q4 results, which came in line in terms of revenues, while margins cam...
Redeye comments on Better Collectives Q4-results which were in line with preliminary numbers release...
Redeye comments on Freemelt’s Q4 results and the directed share issue.
Net sales and operating profit came in above consensus (Refinitiv) for Q4, although Scanfil's custom...
Sales 15% better, EBIT 0% vs. ABGSCe We cut '23-'24e sales by 5-6% Lowered fair value range to SEK 6...
Weak Q4 due to a soft end market We lower '23e-'24e EBIT by 56-44% Market to remain sluggish in the ...
Redeye welcomes today's news that Acarix has received an important "breakthrough" order from the US ...
